C71T
CANCELLED SECTION 71
08/07/2026
Back to search
Official data from USPTO
CARDIOVANT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CARDIOVANT
ST13
US500000079251678Class
5, 42, 44
Filing
79251678
Registration
5963955
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
08/07/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
12/14/2018
Registration date
01/21/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/07/2026
Last transaction
08/07/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
HISER, CHARLES
Law office
O30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Roivant Sciences GmbH
Representatives
Allison Strickland Ricketts Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of cardiovascular diseasesdisorders and conditions; biological preparations for medical or therapeutic purposes for the treatment of cardiovascular diseasesdisorders and conditions
Class 42
Scientific and technological servicesmedical researchscientific research and analysis in the fields of pharmaceuticals and biomedicine; pharmaceuticalbiomedical and biologic therapeutic research services; scientific research in the fields of pharmaceutical and biological therapeutic preparationsclinical trials and examinations carried out after the introduction of medicines on the market; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticalsbiomedicinesclinical trials and post-market trials
Class 44
Providing health and medical information; providing information relating to the diagnosticprophylactic and therapeutic properties of pharmaceutical preparations and biological preparations for the prevention and treatment of diseasesdisorders and conditions
Publications
History of USPTO decisions and trademark events.
24 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/21/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/22/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/30/2020
FIMP
FINAL DISPOSITION PROCESSED
04/30/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/21/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/05/2019
PUBO
PUBLISHED FOR OPPOSITION
11/05/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/16/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/25/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/25/2019
RFNP
REFUSAL PROCESSED BY IB
04/26/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/18/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/26/2019
RFRR
REFUSAL PROCESSED BY MPU
03/26/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/17/2019
CNRT
NON-FINAL ACTION WRITTEN
03/16/2019
DOCK
ASSIGNED TO EXAMINER
03/12/2019
MAFR
APPLICATION FILING RECEIPT MAILED
02/23/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/19/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/15/2019
Continuous trademark protection
Get notified about every new filing that threatens CARDIOVANT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.